nodes	percent_of_prediction	percent_of_DWPC	metapath
Rimonabant—CNR1—multiple sclerosis	0.674	1	CbGaD
Rimonabant—CYP2D6—Fingolimod—multiple sclerosis	0.0427	0.244	CbGbCtD
Rimonabant—CYP3A4—Fingolimod—multiple sclerosis	0.0271	0.155	CbGbCtD
Rimonabant—CYP3A4—Methylprednisolone—multiple sclerosis	0.0175	0.1	CbGbCtD
Rimonabant—CYP3A4—Triamcinolone—multiple sclerosis	0.0133	0.0758	CbGbCtD
Rimonabant—CYP3A4—Mitoxantrone—multiple sclerosis	0.0128	0.073	CbGbCtD
Rimonabant—CYP2C9—Dexamethasone—multiple sclerosis	0.0114	0.065	CbGbCtD
Rimonabant—CYP3A4—Betamethasone—multiple sclerosis	0.0114	0.065	CbGbCtD
Rimonabant—CYP3A4—Prednisolone—multiple sclerosis	0.0112	0.0642	CbGbCtD
Rimonabant—CYP3A4—Prednisone—multiple sclerosis	0.0106	0.0606	CbGbCtD
Rimonabant—CYP2D6—Dexamethasone—multiple sclerosis	0.0104	0.0595	CbGbCtD
Rimonabant—CYP3A4—Dexamethasone—multiple sclerosis	0.00662	0.0378	CbGbCtD
Rimonabant—Pruritus—Fingolimod—multiple sclerosis	0.000415	0.0055	CcSEcCtD
Rimonabant—Mental disorder—Cladribine—multiple sclerosis	0.00041	0.00543	CcSEcCtD
Rimonabant—Malnutrition—Cladribine—multiple sclerosis	0.000407	0.0054	CcSEcCtD
Rimonabant—Diarrhoea—Fingolimod—multiple sclerosis	0.000401	0.00532	CcSEcCtD
Rimonabant—Dizziness—Fingolimod—multiple sclerosis	0.000388	0.00514	CcSEcCtD
Rimonabant—Headache—Fingolimod—multiple sclerosis	0.000367	0.00487	CcSEcCtD
Rimonabant—Hiccups—Prednisone—multiple sclerosis	0.000365	0.00484	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Mitoxantrone—multiple sclerosis	0.000357	0.00473	CcSEcCtD
Rimonabant—Amnesia—Methylprednisolone—multiple sclerosis	0.000356	0.00472	CcSEcCtD
Rimonabant—Anxiety—Cladribine—multiple sclerosis	0.000346	0.00458	CcSEcCtD
Rimonabant—Mood swings—Prednisolone—multiple sclerosis	0.000345	0.00458	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000344	0.00456	CcSEcCtD
Rimonabant—Mediastinal disorder—Azathioprine—multiple sclerosis	0.000343	0.00454	CcSEcCtD
Rimonabant—Infection—Cladribine—multiple sclerosis	0.00033	0.00438	CcSEcCtD
Rimonabant—Psychotic disorder—Methylprednisolone—multiple sclerosis	0.000327	0.00433	CcSEcCtD
Rimonabant—Nervous system disorder—Cladribine—multiple sclerosis	0.000326	0.00432	CcSEcCtD
Rimonabant—Skin disorder—Cladribine—multiple sclerosis	0.000323	0.00428	CcSEcCtD
Rimonabant—Sinusitis—Mitoxantrone—multiple sclerosis	0.000321	0.00426	CcSEcCtD
Rimonabant—Hyperhidrosis—Cladribine—multiple sclerosis	0.000321	0.00426	CcSEcCtD
Rimonabant—Irritability—Methylprednisolone—multiple sclerosis	0.000319	0.00423	CcSEcCtD
Rimonabant—Mood swings—Triamcinolone—multiple sclerosis	0.000318	0.00421	CcSEcCtD
Rimonabant—Mood swings—Methylprednisolone—multiple sclerosis	0.000317	0.0042	CcSEcCtD
Rimonabant—Anorexia—Cladribine—multiple sclerosis	0.000317	0.0042	CcSEcCtD
Rimonabant—Lethargy—Betamethasone—multiple sclerosis	0.000311	0.00411	CcSEcCtD
Rimonabant—Lethargy—Dexamethasone—multiple sclerosis	0.000311	0.00411	CcSEcCtD
Rimonabant—Insomnia—Cladribine—multiple sclerosis	0.000301	0.00398	CcSEcCtD
Rimonabant—Paraesthesia—Cladribine—multiple sclerosis	0.000298	0.00396	CcSEcCtD
Rimonabant—Psychotic disorder—Betamethasone—multiple sclerosis	0.000297	0.00394	CcSEcCtD
Rimonabant—Psychotic disorder—Dexamethasone—multiple sclerosis	0.000297	0.00394	CcSEcCtD
Rimonabant—Irritability—Dexamethasone—multiple sclerosis	0.00029	0.00385	CcSEcCtD
Rimonabant—Irritability—Betamethasone—multiple sclerosis	0.00029	0.00385	CcSEcCtD
Rimonabant—Influenza—Triamcinolone—multiple sclerosis	0.00029	0.00384	CcSEcCtD
Rimonabant—Decreased appetite—Cladribine—multiple sclerosis	0.000289	0.00383	CcSEcCtD
Rimonabant—Mood swings—Dexamethasone—multiple sclerosis	0.000288	0.00382	CcSEcCtD
Rimonabant—Mood swings—Betamethasone—multiple sclerosis	0.000288	0.00382	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000287	0.0038	CcSEcCtD
Rimonabant—Fatigue—Cladribine—multiple sclerosis	0.000287	0.0038	CcSEcCtD
Rimonabant—Amnesia—Prednisone—multiple sclerosis	0.000282	0.00374	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.00028	0.00371	CcSEcCtD
Rimonabant—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000272	0.0036	CcSEcCtD
Rimonabant—Lethargy—Prednisone—multiple sclerosis	0.00027	0.00358	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.000269	0.00357	CcSEcCtD
Rimonabant—Infection—Azathioprine—multiple sclerosis	0.000268	0.00356	CcSEcCtD
Rimonabant—Abdominal pain—Cladribine—multiple sclerosis	0.000263	0.00348	CcSEcCtD
Rimonabant—Skin disorder—Azathioprine—multiple sclerosis	0.000263	0.00348	CcSEcCtD
Rimonabant—Psychotic disorder—Prednisone—multiple sclerosis	0.000259	0.00343	CcSEcCtD
Rimonabant—Infestation—Methylprednisolone—multiple sclerosis	0.000258	0.00342	CcSEcCtD
Rimonabant—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000258	0.00342	CcSEcCtD
Rimonabant—Irritability—Prednisone—multiple sclerosis	0.000253	0.00335	CcSEcCtD
Rimonabant—Mood swings—Prednisone—multiple sclerosis	0.000251	0.00333	CcSEcCtD
Rimonabant—Asthenia—Cladribine—multiple sclerosis	0.000238	0.00316	CcSEcCtD
Rimonabant—Pruritus—Cladribine—multiple sclerosis	0.000235	0.00312	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000233	0.00309	CcSEcCtD
Rimonabant—Convulsion—Mitoxantrone—multiple sclerosis	0.000232	0.00307	CcSEcCtD
Rimonabant—Hallucination—Methylprednisolone—multiple sclerosis	0.00023	0.00305	CcSEcCtD
Rimonabant—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000227	0.00301	CcSEcCtD
Rimonabant—Diarrhoea—Cladribine—multiple sclerosis	0.000227	0.00301	CcSEcCtD
Rimonabant—Anxiety—Mitoxantrone—multiple sclerosis	0.000227	0.00301	CcSEcCtD
Rimonabant—Lethargy—Methotrexate—multiple sclerosis	0.000226	0.00299	CcSEcCtD
Rimonabant—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000221	0.00293	CcSEcCtD
Rimonabant—Dizziness—Cladribine—multiple sclerosis	0.00022	0.00291	CcSEcCtD
Rimonabant—Infection—Mitoxantrone—multiple sclerosis	0.000217	0.00288	CcSEcCtD
Rimonabant—Abdominal pain—Azathioprine—multiple sclerosis	0.000214	0.00283	CcSEcCtD
Rimonabant—Skin disorder—Mitoxantrone—multiple sclerosis	0.000212	0.00281	CcSEcCtD
Rimonabant—Irritability—Methotrexate—multiple sclerosis	0.000211	0.0028	CcSEcCtD
Rimonabant—Vomiting—Cladribine—multiple sclerosis	0.000211	0.0028	CcSEcCtD
Rimonabant—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000211	0.0028	CcSEcCtD
Rimonabant—Angiopathy—Methylprednisolone—multiple sclerosis	0.00021	0.00278	CcSEcCtD
Rimonabant—Mood swings—Methotrexate—multiple sclerosis	0.00021	0.00278	CcSEcCtD
Rimonabant—Rash—Cladribine—multiple sclerosis	0.00021	0.00278	CcSEcCtD
Rimonabant—Hallucination—Dexamethasone—multiple sclerosis	0.000209	0.00278	CcSEcCtD
Rimonabant—Hallucination—Betamethasone—multiple sclerosis	0.000209	0.00278	CcSEcCtD
Rimonabant—Dermatitis—Cladribine—multiple sclerosis	0.000209	0.00277	CcSEcCtD
Rimonabant—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000209	0.00276	CcSEcCtD
Rimonabant—Anorexia—Mitoxantrone—multiple sclerosis	0.000208	0.00276	CcSEcCtD
Rimonabant—Headache—Cladribine—multiple sclerosis	0.000208	0.00276	CcSEcCtD
Rimonabant—Depression—Prednisone—multiple sclerosis	0.000204	0.0027	CcSEcCtD
Rimonabant—Mental disorder—Methylprednisolone—multiple sclerosis	0.000203	0.00269	CcSEcCtD
Rimonabant—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000202	0.00269	CbGpPWpGaD
Rimonabant—Malnutrition—Methylprednisolone—multiple sclerosis	0.000202	0.00267	CcSEcCtD
Rimonabant—Nausea—Cladribine—multiple sclerosis	0.000197	0.00262	CcSEcCtD
Rimonabant—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000196	0.0026	CcSEcCtD
Rimonabant—CNR2—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000195	0.0026	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—CCR1—multiple sclerosis	0.000195	0.0026	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—GPR65—multiple sclerosis	0.000194	0.00258	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—CCL3—multiple sclerosis	0.000193	0.00257	CbGpPWpGaD
Rimonabant—Angiopathy—Betamethasone—multiple sclerosis	0.000191	0.00253	CcSEcCtD
Rimonabant—Angiopathy—Dexamethasone—multiple sclerosis	0.000191	0.00253	CcSEcCtD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.00019	0.00254	CbGpPWpGaD
Rimonabant—Convulsion—Prednisolone—multiple sclerosis	0.00019	0.00252	CcSEcCtD
Rimonabant—Decreased appetite—Mitoxantrone—multiple sclerosis	0.00019	0.00252	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—S1PR1—multiple sclerosis	0.000188	0.00251	CbGpPWpGaD
Rimonabant—Fatigue—Mitoxantrone—multiple sclerosis	0.000188	0.0025	CcSEcCtD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000188	0.00251	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—LINGO1—multiple sclerosis	0.000187	0.00249	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—PTGER4—multiple sclerosis	0.000186	0.00247	CbGpPWpGaD
Rimonabant—CNR1—G alpha (i) signalling events—CCR5—multiple sclerosis	0.000186	0.00247	CbGpPWpGaD
Rimonabant—CNR2—G alpha (i) signalling events—POMC—multiple sclerosis	0.000185	0.00246	CbGpPWpGaD
Rimonabant—Diarrhoea—Azathioprine—multiple sclerosis	0.000185	0.00245	CcSEcCtD
Rimonabant—CNR2—GPCR ligand binding—CXCL10—multiple sclerosis	0.000185	0.00246	CbGpPWpGaD
Rimonabant—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000184	0.00245	CbGpPWpGaD
Rimonabant—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000184	0.00243	CcSEcCtD
Rimonabant—Hallucination—Prednisone—multiple sclerosis	0.000182	0.00242	CcSEcCtD
Rimonabant—Connective tissue disorder—Prednisone—multiple sclerosis	0.00018	0.00239	CcSEcCtD
Rimonabant—CNR1—GPCR ligand binding—CXCR3—multiple sclerosis	0.000179	0.00239	CbGpPWpGaD
Rimonabant—Dizziness—Azathioprine—multiple sclerosis	0.000179	0.00237	CcSEcCtD
Rimonabant—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000179	0.00237	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000178	0.00236	CcSEcCtD
Rimonabant—CNR2—Signaling by GPCR—CCR1—multiple sclerosis	0.000177	0.00236	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CXCL13—multiple sclerosis	0.000177	0.00236	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—RGS1—multiple sclerosis	0.000176	0.00235	CbGpPWpGaD
Rimonabant—Convulsion—Triamcinolone—multiple sclerosis	0.000175	0.00232	CcSEcCtD
Rimonabant—Convulsion—Methylprednisolone—multiple sclerosis	0.000175	0.00231	CcSEcCtD
Rimonabant—CNR1—GPCR ligand binding—CCR2—multiple sclerosis	0.000174	0.00232	CbGpPWpGaD
Rimonabant—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000173	0.0023	CcSEcCtD
Rimonabant—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000173	0.00229	CcSEcCtD
Rimonabant—CNR1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000172	0.00229	CbGpPWpGaD
Rimonabant—Vomiting—Azathioprine—multiple sclerosis	0.000172	0.00228	CcSEcCtD
Rimonabant—Anxiety—Methylprednisolone—multiple sclerosis	0.000171	0.00227	CcSEcCtD
Rimonabant—Infestation—Methotrexate—multiple sclerosis	0.000171	0.00226	CcSEcCtD
Rimonabant—Infestation NOS—Methotrexate—multiple sclerosis	0.000171	0.00226	CcSEcCtD
Rimonabant—Rash—Azathioprine—multiple sclerosis	0.00017	0.00226	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.00017	0.00226	CcSEcCtD
Rimonabant—Dermatitis—Azathioprine—multiple sclerosis	0.00017	0.00226	CcSEcCtD
Rimonabant—Depression—Methotrexate—multiple sclerosis	0.00017	0.00226	CcSEcCtD
Rimonabant—Headache—Azathioprine—multiple sclerosis	0.000169	0.00224	CcSEcCtD
Rimonabant—Dry mouth—Triamcinolone—multiple sclerosis	0.000168	0.00223	CcSEcCtD
Rimonabant—CNR1—GPCR downstream signaling—GPR65—multiple sclerosis	0.000167	0.00223	CbGpPWpGaD
Rimonabant—Angiopathy—Prednisone—multiple sclerosis	0.000166	0.0022	CcSEcCtD
Rimonabant—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000166	0.00221	CbGpPWpGaD
Rimonabant—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000166	0.00221	CbGpPWpGaD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000164	0.00218	CbGpPWpGaD
Rimonabant—Infection—Triamcinolone—multiple sclerosis	0.000164	0.00217	CcSEcCtD
Rimonabant—Infection—Methylprednisolone—multiple sclerosis	0.000163	0.00217	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—TAGAP—multiple sclerosis	0.000162	0.00216	CbGpPWpGaD
Rimonabant—Insomnia—Prednisolone—multiple sclerosis	0.000162	0.00215	CcSEcCtD
Rimonabant—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000161	0.00214	CcSEcCtD
Rimonabant—Paraesthesia—Prednisolone—multiple sclerosis	0.000161	0.00213	CcSEcCtD
Rimonabant—Mental disorder—Prednisone—multiple sclerosis	0.000161	0.00213	CcSEcCtD
Rimonabant—Nausea—Azathioprine—multiple sclerosis	0.000161	0.00213	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—RGS1—multiple sclerosis	0.00016	0.00213	CbGpPWpGaD
Rimonabant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00016	0.00213	CbGpPWpGaD
Rimonabant—Skin disorder—Methylprednisolone—multiple sclerosis	0.00016	0.00212	CcSEcCtD
Rimonabant—Malnutrition—Prednisone—multiple sclerosis	0.00016	0.00211	CcSEcCtD
Rimonabant—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000159	0.00211	CcSEcCtD
Rimonabant—CNR2—GPCR ligand binding—CCL5—multiple sclerosis	0.000159	0.00212	CbGpPWpGaD
Rimonabant—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000159	0.00211	CcSEcCtD
Rimonabant—Convulsion—Betamethasone—multiple sclerosis	0.000159	0.0021	CcSEcCtD
Rimonabant—Convulsion—Dexamethasone—multiple sclerosis	0.000159	0.0021	CcSEcCtD
Rimonabant—Asthenia—Mitoxantrone—multiple sclerosis	0.000157	0.00208	CcSEcCtD
Rimonabant—Anxiety—Dexamethasone—multiple sclerosis	0.000155	0.00206	CcSEcCtD
Rimonabant—Anxiety—Betamethasone—multiple sclerosis	0.000155	0.00206	CcSEcCtD
Rimonabant—CNR1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000153	0.00204	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—CCR1—multiple sclerosis	0.000153	0.00204	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—GPR65—multiple sclerosis	0.000152	0.00202	CbGpPWpGaD
Rimonabant—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000149	0.00198	CcSEcCtD
Rimonabant—Insomnia—Triamcinolone—multiple sclerosis	0.000149	0.00198	CcSEcCtD
Rimonabant—Insomnia—Methylprednisolone—multiple sclerosis	0.000149	0.00197	CcSEcCtD
Rimonabant—Infection—Dexamethasone—multiple sclerosis	0.000149	0.00197	CcSEcCtD
Rimonabant—Infection—Betamethasone—multiple sclerosis	0.000149	0.00197	CcSEcCtD
Rimonabant—Paraesthesia—Triamcinolone—multiple sclerosis	0.000148	0.00196	CcSEcCtD
Rimonabant—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000148	0.00196	CcSEcCtD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000148	0.00197	CbGpPWpGaD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000147	0.00196	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—LINGO1—multiple sclerosis	0.000147	0.00196	CbGpPWpGaD
Rimonabant—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000147	0.00196	CbGpPWpGaD
Rimonabant—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000147	0.00194	CcSEcCtD
Rimonabant—Nervous system disorder—Betamethasone—multiple sclerosis	0.000147	0.00194	CcSEcCtD
Rimonabant—CNR1—G alpha (i) signalling events—POMC—multiple sclerosis	0.000145	0.00193	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000145	0.00193	CbGpPWpGaD
Rimonabant—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000145	0.00192	CcSEcCtD
Rimonabant—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000145	0.00192	CcSEcCtD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000144	0.00192	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—CCR5—multiple sclerosis	0.000143	0.00191	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000143	0.0019	CbGpPWpGaD
Rimonabant—Anorexia—Betamethasone—multiple sclerosis	0.000143	0.00189	CcSEcCtD
Rimonabant—Anorexia—Dexamethasone—multiple sclerosis	0.000143	0.00189	CcSEcCtD
Rimonabant—Fatigue—Triamcinolone—multiple sclerosis	0.000142	0.00188	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—S1PR1—multiple sclerosis	0.000142	0.00189	CbGpPWpGaD
Rimonabant—Fatigue—Methylprednisolone—multiple sclerosis	0.000142	0.00188	CcSEcCtD
Rimonabant—Angiopathy—Methotrexate—multiple sclerosis	0.000139	0.00184	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000139	0.00185	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CCR1—multiple sclerosis	0.000139	0.00185	CbGpPWpGaD
Rimonabant—Vomiting—Mitoxantrone—multiple sclerosis	0.000139	0.00184	CcSEcCtD
Rimonabant—Convulsion—Prednisone—multiple sclerosis	0.000138	0.00183	CcSEcCtD
Rimonabant—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000138	0.00183	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—GPC5—multiple sclerosis	0.000138	0.00184	CbGpPWpGaD
Rimonabant—Rash—Mitoxantrone—multiple sclerosis	0.000138	0.00183	CcSEcCtD
Rimonabant—Dermatitis—Mitoxantrone—multiple sclerosis	0.000138	0.00182	CcSEcCtD
Rimonabant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000137	0.00182	CbGpPWpGaD
Rimonabant—Headache—Mitoxantrone—multiple sclerosis	0.000137	0.00181	CcSEcCtD
Rimonabant—Anxiety—Prednisone—multiple sclerosis	0.000135	0.00179	CcSEcCtD
Rimonabant—Insomnia—Dexamethasone—multiple sclerosis	0.000135	0.00179	CcSEcCtD
Rimonabant—Insomnia—Betamethasone—multiple sclerosis	0.000135	0.00179	CcSEcCtD
Rimonabant—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000135	0.0018	CbGpPWpGaD
Rimonabant—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000135	0.0018	CbGpPWpGaD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000135	0.00179	CcSEcCtD
Rimonabant—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000134	0.00178	CcSEcCtD
Rimonabant—Paraesthesia—Dexamethasone—multiple sclerosis	0.000134	0.00178	CcSEcCtD
Rimonabant—Paraesthesia—Betamethasone—multiple sclerosis	0.000134	0.00178	CcSEcCtD
Rimonabant—Mental disorder—Methotrexate—multiple sclerosis	0.000134	0.00178	CcSEcCtD
Rimonabant—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000134	0.00178	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000134	0.00178	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000134	0.00178	CbGpPWpGaD
Rimonabant—CNR1—BDNF signaling pathway—STAT3—multiple sclerosis	0.000134	0.00178	CbGpPWpGaD
Rimonabant—Malnutrition—Methotrexate—multiple sclerosis	0.000133	0.00177	CcSEcCtD
Rimonabant—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000133	0.00177	CbGpPWpGaD
Rimonabant—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000133	0.00177	CbGpPWpGaD
Rimonabant—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000132	0.00176	CbGpPWpGaD
Rimonabant—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000132	0.00176	CbGpPWpGaD
Rimonabant—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00013	0.00172	CcSEcCtD
Rimonabant—Decreased appetite—Dexamethasone—multiple sclerosis	0.00013	0.00172	CcSEcCtD
Rimonabant—Decreased appetite—Betamethasone—multiple sclerosis	0.00013	0.00172	CcSEcCtD
Rimonabant—Nausea—Mitoxantrone—multiple sclerosis	0.00013	0.00172	CcSEcCtD
Rimonabant—Infection—Prednisone—multiple sclerosis	0.000129	0.00171	CcSEcCtD
Rimonabant—CNR2—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000129	0.00172	CbGpPWpGaD
Rimonabant—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000129	0.00171	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000129	0.00171	CcSEcCtD
Rimonabant—Fatigue—Betamethasone—multiple sclerosis	0.000129	0.00171	CcSEcCtD
Rimonabant—Fatigue—Dexamethasone—multiple sclerosis	0.000129	0.00171	CcSEcCtD
Rimonabant—Nervous system disorder—Prednisone—multiple sclerosis	0.000128	0.00169	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—TAGAP—multiple sclerosis	0.000127	0.0017	CbGpPWpGaD
Rimonabant—Skin disorder—Prednisone—multiple sclerosis	0.000127	0.00168	CcSEcCtD
Rimonabant—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000126	0.00168	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CCL3—multiple sclerosis	0.000126	0.00168	CbGpPWpGaD
Rimonabant—Hyperhidrosis—Prednisone—multiple sclerosis	0.000126	0.00167	CcSEcCtD
Rimonabant—CNR2—GPCR downstream signaling—CCR2—multiple sclerosis	0.000126	0.00167	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—CCL5—multiple sclerosis	0.000125	0.00166	CbGpPWpGaD
Rimonabant—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000124	0.00166	CbGpPWpGaD
Rimonabant—Anorexia—Prednisone—multiple sclerosis	0.000124	0.00165	CcSEcCtD
Rimonabant—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000122	0.00162	CcSEcCtD
Rimonabant—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000122	0.00162	CcSEcCtD
Rimonabant—CNR2—Signaling by GPCR—PTGER4—multiple sclerosis	0.000121	0.00162	CbGpPWpGaD
Rimonabant—CNR1—BDNF signaling pathway—MAPK1—multiple sclerosis	0.000121	0.00162	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—RGS1—multiple sclerosis	0.000121	0.00161	CbGpPWpGaD
Rimonabant—Dizziness—Prednisolone—multiple sclerosis	0.000119	0.00157	CcSEcCtD
Rimonabant—Asthenia—Triamcinolone—multiple sclerosis	0.000118	0.00157	CcSEcCtD
Rimonabant—Abdominal pain—Dexamethasone—multiple sclerosis	0.000118	0.00157	CcSEcCtD
Rimonabant—Abdominal pain—Betamethasone—multiple sclerosis	0.000118	0.00157	CcSEcCtD
Rimonabant—Asthenia—Methylprednisolone—multiple sclerosis	0.000118	0.00156	CcSEcCtD
Rimonabant—Insomnia—Prednisone—multiple sclerosis	0.000118	0.00156	CcSEcCtD
Rimonabant—CNR2—Signaling by GPCR—CXCR3—multiple sclerosis	0.000117	0.00156	CbGpPWpGaD
Rimonabant—Paraesthesia—Prednisone—multiple sclerosis	0.000117	0.00155	CcSEcCtD
Rimonabant—Pruritus—Triamcinolone—multiple sclerosis	0.000117	0.00155	CcSEcCtD
Rimonabant—Pruritus—Methylprednisolone—multiple sclerosis	0.000116	0.00154	CcSEcCtD
Rimonabant—CNR2—GPCR downstream signaling—CNR1—multiple sclerosis	0.000116	0.00154	CbGpPWpGaD
Rimonabant—Convulsion—Methotrexate—multiple sclerosis	0.000116	0.00153	CcSEcCtD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000115	0.00154	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—GPR65—multiple sclerosis	0.000114	0.00152	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000114	0.00152	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000114	0.00152	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CCR2—multiple sclerosis	0.000114	0.00152	CbGpPWpGaD
Rimonabant—Decreased appetite—Prednisone—multiple sclerosis	0.000113	0.0015	CcSEcCtD
Rimonabant—Rash—Prednisolone—multiple sclerosis	0.000113	0.0015	CcSEcCtD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000113	0.0015	CbGpPWpGaD
Rimonabant—Dermatitis—Prednisolone—multiple sclerosis	0.000113	0.0015	CcSEcCtD
Rimonabant—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000113	0.0015	CbGpPWpGaD
Rimonabant—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000113	0.0015	CbGpPWpGaD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000113	0.00149	CcSEcCtD
Rimonabant—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000113	0.00149	CcSEcCtD
Rimonabant—CNR1—GPCR ligand binding—CCR5—multiple sclerosis	0.000112	0.0015	CbGpPWpGaD
Rimonabant—Fatigue—Prednisone—multiple sclerosis	0.000112	0.00149	CcSEcCtD
Rimonabant—Headache—Prednisolone—multiple sclerosis	0.000112	0.00149	CcSEcCtD
Rimonabant—CNR2—GPCR ligand binding—POMC—multiple sclerosis	0.000112	0.00149	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—S1PR1—multiple sclerosis	0.000111	0.00148	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—CCL2—multiple sclerosis	0.00011	0.00146	CbGpPWpGaD
Rimonabant—Dizziness—Triamcinolone—multiple sclerosis	0.000109	0.00144	CcSEcCtD
Rimonabant—Dizziness—Methylprednisolone—multiple sclerosis	0.000109	0.00144	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—GPC5—multiple sclerosis	0.000108	0.00144	CbGpPWpGaD
Rimonabant—Infection—Methotrexate—multiple sclerosis	0.000108	0.00143	CcSEcCtD
Rimonabant—Asthenia—Dexamethasone—multiple sclerosis	0.000107	0.00142	CcSEcCtD
Rimonabant—Asthenia—Betamethasone—multiple sclerosis	0.000107	0.00142	CcSEcCtD
Rimonabant—Nervous system disorder—Methotrexate—multiple sclerosis	0.000107	0.00141	CcSEcCtD
Rimonabant—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000107	0.00141	CcSEcCtD
Rimonabant—Nausea—Prednisolone—multiple sclerosis	0.000106	0.00141	CcSEcCtD
Rimonabant—Pruritus—Betamethasone—multiple sclerosis	0.000106	0.0014	CcSEcCtD
Rimonabant—Pruritus—Dexamethasone—multiple sclerosis	0.000106	0.0014	CcSEcCtD
Rimonabant—Skin disorder—Methotrexate—multiple sclerosis	0.000106	0.0014	CcSEcCtD
Rimonabant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000106	0.00141	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CNR1—multiple sclerosis	0.000105	0.0014	CbGpPWpGaD
Rimonabant—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000105	0.00139	CcSEcCtD
Rimonabant—CNR1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000105	0.0014	CbGpPWpGaD
Rimonabant—Vomiting—Triamcinolone—multiple sclerosis	0.000105	0.00139	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—CXCL13—multiple sclerosis	0.000105	0.00139	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CCR1—multiple sclerosis	0.000105	0.00139	CbGpPWpGaD
Rimonabant—Vomiting—Methylprednisolone—multiple sclerosis	0.000105	0.00139	CcSEcCtD
Rimonabant—CNR2—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000104	0.00139	CbGpPWpGaD
Rimonabant—Rash—Triamcinolone—multiple sclerosis	0.000104	0.00138	CcSEcCtD
Rimonabant—Dermatitis—Triamcinolone—multiple sclerosis	0.000104	0.00138	CcSEcCtD
Rimonabant—Anorexia—Methotrexate—multiple sclerosis	0.000104	0.00137	CcSEcCtD
Rimonabant—Rash—Methylprednisolone—multiple sclerosis	0.000104	0.00137	CcSEcCtD
Rimonabant—Dermatitis—Methylprednisolone—multiple sclerosis	0.000104	0.00137	CcSEcCtD
Rimonabant—Headache—Triamcinolone—multiple sclerosis	0.000103	0.00137	CcSEcCtD
Rimonabant—Headache—Methylprednisolone—multiple sclerosis	0.000103	0.00137	CcSEcCtD
Rimonabant—Abdominal pain—Prednisone—multiple sclerosis	0.000103	0.00136	CcSEcCtD
Rimonabant—Diarrhoea—Betamethasone—multiple sclerosis	0.000102	0.00136	CcSEcCtD
Rimonabant—Diarrhoea—Dexamethasone—multiple sclerosis	0.000102	0.00136	CcSEcCtD
Rimonabant—CNR1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000101	0.00135	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CCL3—multiple sclerosis	9.9e-05	0.00132	CbGpPWpGaD
Rimonabant—Dizziness—Betamethasone—multiple sclerosis	9.89e-05	0.00131	CcSEcCtD
Rimonabant—Dizziness—Dexamethasone—multiple sclerosis	9.89e-05	0.00131	CcSEcCtD
Rimonabant—CNR1—GPCR downstream signaling—CCR2—multiple sclerosis	9.86e-05	0.00131	CbGpPWpGaD
Rimonabant—Insomnia—Methotrexate—multiple sclerosis	9.85e-05	0.0013	CcSEcCtD
Rimonabant—Nausea—Triamcinolone—multiple sclerosis	9.79e-05	0.0013	CcSEcCtD
Rimonabant—Paraesthesia—Methotrexate—multiple sclerosis	9.77e-05	0.0013	CcSEcCtD
Rimonabant—Nausea—Methylprednisolone—multiple sclerosis	9.77e-05	0.00129	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—PTGER4—multiple sclerosis	9.53e-05	0.00127	CbGpPWpGaD
Rimonabant—Vomiting—Dexamethasone—multiple sclerosis	9.51e-05	0.00126	CcSEcCtD
Rimonabant—Vomiting—Betamethasone—multiple sclerosis	9.51e-05	0.00126	CcSEcCtD
Rimonabant—CNR2—Signaling by GPCR—CXCL10—multiple sclerosis	9.48e-05	0.00126	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—RGS1—multiple sclerosis	9.47e-05	0.00126	CbGpPWpGaD
Rimonabant—Decreased appetite—Methotrexate—multiple sclerosis	9.46e-05	0.00125	CcSEcCtD
Rimonabant—Rash—Dexamethasone—multiple sclerosis	9.43e-05	0.00125	CcSEcCtD
Rimonabant—Rash—Betamethasone—multiple sclerosis	9.43e-05	0.00125	CcSEcCtD
Rimonabant—Dermatitis—Dexamethasone—multiple sclerosis	9.42e-05	0.00125	CcSEcCtD
Rimonabant—Dermatitis—Betamethasone—multiple sclerosis	9.42e-05	0.00125	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Methotrexate—multiple sclerosis	9.4e-05	0.00125	CcSEcCtD
Rimonabant—Fatigue—Methotrexate—multiple sclerosis	9.38e-05	0.00124	CcSEcCtD
Rimonabant—Headache—Dexamethasone—multiple sclerosis	9.37e-05	0.00124	CcSEcCtD
Rimonabant—Headache—Betamethasone—multiple sclerosis	9.37e-05	0.00124	CcSEcCtD
Rimonabant—Asthenia—Prednisone—multiple sclerosis	9.34e-05	0.00124	CcSEcCtD
Rimonabant—Pruritus—Prednisone—multiple sclerosis	9.21e-05	0.00122	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—CXCR3—multiple sclerosis	9.21e-05	0.00123	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—CCL5—multiple sclerosis	8.99e-05	0.0012	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—GPR65—multiple sclerosis	8.98e-05	0.0012	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CCR2—multiple sclerosis	8.95e-05	0.00119	CbGpPWpGaD
Rimonabant—Diarrhoea—Prednisone—multiple sclerosis	8.91e-05	0.00118	CcSEcCtD
Rimonabant—Gastrointestinal pain—Methotrexate—multiple sclerosis	8.9e-05	0.00118	CcSEcCtD
Rimonabant—Nausea—Dexamethasone—multiple sclerosis	8.88e-05	0.00118	CcSEcCtD
Rimonabant—Nausea—Betamethasone—multiple sclerosis	8.88e-05	0.00118	CcSEcCtD
Rimonabant—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	8.83e-05	0.00118	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	8.83e-05	0.00118	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—POMC—multiple sclerosis	8.79e-05	0.00117	CbGpPWpGaD
Rimonabant—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.71e-05	0.00116	CbGpPWpGaD
Rimonabant—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.71e-05	0.00116	CbGpPWpGaD
Rimonabant—Dizziness—Prednisone—multiple sclerosis	8.61e-05	0.00114	CcSEcCtD
Rimonabant—Abdominal pain—Methotrexate—multiple sclerosis	8.6e-05	0.00114	CcSEcCtD
Rimonabant—CNR1—GPCR ligand binding—CCL2—multiple sclerosis	8.6e-05	0.00114	CbGpPWpGaD
Rimonabant—Vomiting—Prednisone—multiple sclerosis	8.28e-05	0.0011	CcSEcCtD
Rimonabant—Rash—Prednisone—multiple sclerosis	8.21e-05	0.00109	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—CCR1—multiple sclerosis	8.21e-05	0.00109	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CXCL13—multiple sclerosis	8.21e-05	0.00109	CbGpPWpGaD
Rimonabant—Dermatitis—Prednisone—multiple sclerosis	8.2e-05	0.00109	CcSEcCtD
Rimonabant—CNR1—GPCR downstream signaling—CXCL10—multiple sclerosis	8.19e-05	0.00109	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CCL5—multiple sclerosis	8.16e-05	0.00109	CbGpPWpGaD
Rimonabant—Headache—Prednisone—multiple sclerosis	8.16e-05	0.00108	CcSEcCtD
Rimonabant—CNR2—GPCR downstream signaling—CCR5—multiple sclerosis	8.1e-05	0.00108	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—IL2RA—multiple sclerosis	7.98e-05	0.00106	CbGpPWpGaD
Rimonabant—Asthenia—Methotrexate—multiple sclerosis	7.81e-05	0.00103	CcSEcCtD
Rimonabant—Nausea—Prednisone—multiple sclerosis	7.74e-05	0.00103	CcSEcCtD
Rimonabant—Pruritus—Methotrexate—multiple sclerosis	7.7e-05	0.00102	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—CCL3—multiple sclerosis	7.45e-05	0.000993	CbGpPWpGaD
Rimonabant—Diarrhoea—Methotrexate—multiple sclerosis	7.45e-05	0.000987	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—CXCL10—multiple sclerosis	7.44e-05	0.000991	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CCR5—multiple sclerosis	7.35e-05	0.000979	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL2RA—multiple sclerosis	7.25e-05	0.000965	CbGpPWpGaD
Rimonabant—Dizziness—Methotrexate—multiple sclerosis	7.2e-05	0.000954	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—PTGER4—multiple sclerosis	7.18e-05	0.000955	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PGR—multiple sclerosis	7.07e-05	0.000941	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—CCL5—multiple sclerosis	7.05e-05	0.000939	CbGpPWpGaD
Rimonabant—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.05e-05	0.000939	CbGpPWpGaD
Rimonabant—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.99e-05	0.000931	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CXCR3—multiple sclerosis	6.93e-05	0.000923	CbGpPWpGaD
Rimonabant—Vomiting—Methotrexate—multiple sclerosis	6.92e-05	0.000917	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—CD28—multiple sclerosis	6.87e-05	0.000914	CbGpPWpGaD
Rimonabant—Rash—Methotrexate—multiple sclerosis	6.86e-05	0.000909	CcSEcCtD
Rimonabant—Dermatitis—Methotrexate—multiple sclerosis	6.86e-05	0.000909	CcSEcCtD
Rimonabant—Headache—Methotrexate—multiple sclerosis	6.82e-05	0.000904	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—CCR2—multiple sclerosis	6.74e-05	0.000898	CbGpPWpGaD
Rimonabant—Nausea—Methotrexate—multiple sclerosis	6.47e-05	0.000857	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—CCL5—multiple sclerosis	6.41e-05	0.000853	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—CCR5—multiple sclerosis	6.35e-05	0.000846	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—POMC—multiple sclerosis	6.33e-05	0.000843	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—IL2RA—multiple sclerosis	6.26e-05	0.000834	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CNR1—multiple sclerosis	6.22e-05	0.000828	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	6.15e-05	0.000819	CbGpPWpGaD
Rimonabant—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.97e-05	0.000795	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CCL3—multiple sclerosis	5.85e-05	0.000779	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CCR5—multiple sclerosis	5.77e-05	0.000768	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—POMC—multiple sclerosis	5.75e-05	0.000765	CbGpPWpGaD
Rimonabant—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.72e-05	0.000761	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL2RA—multiple sclerosis	5.69e-05	0.000757	CbGpPWpGaD
Rimonabant—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.67e-05	0.000755	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PTGER4—multiple sclerosis	5.63e-05	0.00075	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CCL2—multiple sclerosis	5.62e-05	0.000749	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CXCL10—multiple sclerosis	5.6e-05	0.000746	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PGR—multiple sclerosis	5.55e-05	0.000738	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	5.48e-05	0.00073	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	5.46e-05	0.000727	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CXCR3—multiple sclerosis	5.44e-05	0.000724	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CD28—multiple sclerosis	5.39e-05	0.000717	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CCR2—multiple sclerosis	5.29e-05	0.000704	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.14e-05	0.000684	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.14e-05	0.000684	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—TYK2—multiple sclerosis	5.11e-05	0.00068	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—POMC—multiple sclerosis	4.97e-05	0.000661	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CD86—multiple sclerosis	4.9e-05	0.000652	CbGpPWpGaD
Rimonabant—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.84e-05	0.000645	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CCL5—multiple sclerosis	4.82e-05	0.000642	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—IL2—multiple sclerosis	4.68e-05	0.000623	CbGpPWpGaD
Rimonabant—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.61e-05	0.000614	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—POMC—multiple sclerosis	4.51e-05	0.0006	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—SPP1—multiple sclerosis	4.47e-05	0.000595	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CCL2—multiple sclerosis	4.41e-05	0.000588	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CXCL10—multiple sclerosis	4.4e-05	0.000585	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.39e-05	0.000585	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.39e-05	0.000585	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CCR5—multiple sclerosis	4.34e-05	0.000578	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL2RA—multiple sclerosis	4.28e-05	0.00057	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	4.27e-05	0.000569	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	4.26e-05	0.000567	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL2—multiple sclerosis	4.25e-05	0.000566	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	4.18e-05	0.000556	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—TYK2—multiple sclerosis	4.01e-05	0.000534	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	3.98e-05	0.00053	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	3.98e-05	0.00053	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—APOE—multiple sclerosis	3.95e-05	0.000526	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CD86—multiple sclerosis	3.84e-05	0.000512	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CCL5—multiple sclerosis	3.78e-05	0.000504	CbGpPWpGaD
Rimonabant—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.74e-05	0.000498	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—IL2—multiple sclerosis	3.67e-05	0.000489	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CD80—multiple sclerosis	3.57e-05	0.000476	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—SPP1—multiple sclerosis	3.5e-05	0.000467	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CCR5—multiple sclerosis	3.41e-05	0.000454	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—POMC—multiple sclerosis	3.4e-05	0.000452	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IL2RA—multiple sclerosis	3.36e-05	0.000447	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL2—multiple sclerosis	3.33e-05	0.000444	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CCL2—multiple sclerosis	3.32e-05	0.000442	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—SRM—multiple sclerosis	3.28e-05	0.000436	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—MAPK1—multiple sclerosis	3.25e-05	0.000433	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—SRM—multiple sclerosis	3.25e-05	0.000433	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—APOE—multiple sclerosis	3.1e-05	0.000413	CbGpPWpGaD
Rimonabant—CYP2D6—Biological oxidations—POMC—multiple sclerosis	3.04e-05	0.000404	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TYK2—multiple sclerosis	3.02e-05	0.000402	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—POMC—multiple sclerosis	3.01e-05	0.000401	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CD80—multiple sclerosis	2.8e-05	0.000373	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—SRM—multiple sclerosis	2.78e-05	0.00037	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—POMC—multiple sclerosis	2.66e-05	0.000355	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CCL2—multiple sclerosis	2.61e-05	0.000347	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—POMC—multiple sclerosis	2.57e-05	0.000343	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—MAPK1—multiple sclerosis	2.55e-05	0.00034	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL2—multiple sclerosis	2.51e-05	0.000334	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL6—multiple sclerosis	2.5e-05	0.000333	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MMP9—multiple sclerosis	2.38e-05	0.000316	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TYK2—multiple sclerosis	2.37e-05	0.000315	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.31e-05	0.000307	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.31e-05	0.000307	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.29e-05	0.000305	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.29e-05	0.000305	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.24e-05	0.000298	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—SRM—multiple sclerosis	2.14e-05	0.000285	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—STAT3—multiple sclerosis	2.11e-05	0.000281	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—GPC5—multiple sclerosis	2.11e-05	0.000281	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—GPC5—multiple sclerosis	2.09e-05	0.000279	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.99e-05	0.000264	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IL2—multiple sclerosis	1.97e-05	0.000262	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MYC—multiple sclerosis	1.96e-05	0.000261	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL6—multiple sclerosis	1.96e-05	0.000261	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TGFB1—multiple sclerosis	1.96e-05	0.000261	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.96e-05	0.00026	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.96e-05	0.00026	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MAPK1—multiple sclerosis	1.92e-05	0.000256	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.91e-05	0.000255	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MMP9—multiple sclerosis	1.86e-05	0.000248	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.79e-05	0.000238	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.75e-05	0.000233	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.73e-05	0.000231	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—STAT3—multiple sclerosis	1.66e-05	0.000221	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MYC—multiple sclerosis	1.54e-05	0.000205	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TGFB1—multiple sclerosis	1.54e-05	0.000205	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.51e-05	0.000201	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.51e-05	0.000201	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MAPK1—multiple sclerosis	1.51e-05	0.000201	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.48e-05	0.000197	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL6—multiple sclerosis	1.48e-05	0.000196	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.38e-05	0.000184	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.35e-05	0.000179	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IL6—multiple sclerosis	1.16e-05	0.000154	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.16e-05	0.000154	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.15e-05	0.000153	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.14e-05	0.000152	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.05e-05	0.00014	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—BCHE—multiple sclerosis	1e-05	0.000134	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—BCHE—multiple sclerosis	9.96e-06	0.000133	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.88e-06	0.000132	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.01e-06	0.00012	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—BCHE—multiple sclerosis	8.51e-06	0.000113	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.57e-06	8.75e-05	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—APOE—multiple sclerosis	6.05e-06	8.05e-05	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—APOE—multiple sclerosis	5.99e-06	7.98e-05	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—POMC—multiple sclerosis	5.19e-06	6.91e-05	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—POMC—multiple sclerosis	5.15e-06	6.86e-05	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—APOE—multiple sclerosis	5.12e-06	6.82e-05	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—ALB—multiple sclerosis	4.73e-06	6.3e-05	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—ALB—multiple sclerosis	4.69e-06	6.25e-05	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—POMC—multiple sclerosis	4.4e-06	5.86e-05	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—ALB—multiple sclerosis	4.01e-06	5.34e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—APOE—multiple sclerosis	3.95e-06	5.26e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—POMC—multiple sclerosis	3.4e-06	4.52e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—ALB—multiple sclerosis	3.1e-06	4.12e-05	CbGpPWpGaD
